secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001683168-25-002131
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised
--------------------------------------------------------------------------------

- Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.
- Cash at Dec 31, 2024 was $5.4M; subsequent financings added net $6.8M, total $12.1M raised.
- PH-762 Phase 1b: 3rd cohort fully enrolled; in cohort 2, 2 complete responses and 1 partial response out of 4 patients.
- R&D expenses decreased 42% to $3.7M due to cost rationalization and termination of AgonOx agreement.
- Total proceeds of $9.2M from registered direct offerings and $2.9M from warrant exercises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/0001683168-25-002131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-002131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer